DXCM Cash & equivalents
Cash & equivalents at Dexcom rose to $918M in fiscal 2025, from $606M in 2024.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 1093557 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$918M
FY2024 $606M
HIGH$1.1B FY2021
LOW$566M FY2023
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2025 | $918M | +$312M |
| FY2024 | $606M | +$40M |
| FY2023 | $566M | $-76M |
| FY2022 | $642M | $-410M |
| FY2021 | $1.1B | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · DXCM company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.